← Back to Screener
Niagen Bioscience, Inc. Common Stock (NAGE)
Price$3.61
Value ScoreC
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-58.40%
Price vs S&P 500 (4W)-25.38%
VGM Score46.15
Market Capitalization$307.43M
P/E Ratio (Annual)17.69x
All Metrics
P/CF (Annual)22.77x
Book Value / Share (Quarterly)$1.04
P/TBV (Annual)7.16x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)21.56%
Cash Flow / Share (Quarterly)$0.05
Price vs S&P 500 (YTD)-50.24%
Gross Margin (TTM)64.28%
Net Profit Margin (TTM)14.29%
EPS (TTM)$0.22
10-Day Avg Trading Volume1.05M
EPS Excl Extra (TTM)$0.22
Revenue Growth (5Y)16.91%
EPS (Annual)$0.20
ROI (Annual)22.71%
Gross Margin (Annual)64.28%
Net Profit Margin (5Y Avg)-9.42%
Cash / Share (Quarterly)$0.84
P/E Basic Excl Extra (TTM)16.50x
Revenue Growth QoQ (YoY)3.26%
P/E Normalized (Annual)17.69x
ROA (Last FY)16.34%
Revenue Growth TTM (YoY)20.84%
EBITD / Share (TTM)$0.22
ROE (5Y Avg)-23.86%
Operating Margin (TTM)13.70%
Cash Flow / Share (Annual)$0.17
P/B Ratio3.73x
P/B Ratio (Quarterly)4.29x
Net Income / Employee (Annual)$148,600
EV / Revenue (TTM)1.85x
Net Interest Coverage (TTM)-451.17x
ROA (TTM)18.16%
EPS Growth QoQ (YoY)22.86%
EV / EBITDA (TTM)13.07x
EPS Incl Extra (Annual)$0.20
Current Ratio (Annual)4.86x
Quick Ratio (Quarterly)3.49x
3-Month Avg Trading Volume1.12M
52-Week Price Return-64.33%
EV / Free Cash Flow (Annual)18.24x
P/E Incl Extra (TTM)16.50x
Revenue / Employee (TTM)$1,114,700
Tangible BV / Share (Quarterly)$0.97
P/S Ratio (Annual)2.38x
Asset Turnover (Annual)1.22x
52-Week High$14.69
Operating Margin (5Y Avg)-10.47%
EPS Excl Extra (Annual)$0.20
CapEx CAGR (5Y)15.84%
26-Week Price Return-42.47%
Quick Ratio (Annual)3.77x
13-Week Price Return-25.48%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.61x
Enterprise Value$241.03M
Revenue / Share Growth (5Y)9.32%
Asset Turnover (TTM)1.27x
Revenue / Employee (Annual)$1,106,200
Inventory Turnover (Annual)3.12x
Pretax Margin (Annual)14.06%
Cash / Share (Annual)$0.81
3-Month Return Std Dev52.74%
Gross Margin (5Y Avg)61.56%
Net Income / Employee (TTM)$159,300
ROE (Last FY)22.71%
Net Interest Coverage (Annual)-510.50x
EPS Basic Excl Extra (Annual)$0.20
P/FCF (TTM)23.27x
Receivables Turnover (TTM)12.96x
EV / Free Cash Flow (TTM)58.70x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.22
Receivables Turnover (Annual)14.78x
ROI (TTM)25.38%
P/S Ratio (TTM)2.36x
Pretax Margin (5Y Avg)-9.23%
Revenue / Share (Annual)$1.51
Tangible BV / Share (Annual)$0.89
Forward P/E14.72x
Price vs S&P 500 (52W)-92.53%
P/E Ratio (TTM)16.50x
EPS Growth TTM (YoY)26.54%
Year-to-Date Return-39.31%
5-Day Price Return5.46%
EPS Normalized (Annual)$0.20
ROA (5Y Avg)-11.53%
Net Profit Margin (Annual)13.43%
Month-to-Date Return-18.39%
EBITD / Share (Annual)$0.20
Operating Margin (Annual)12.58%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)69.44x
ROI (5Y Avg)-23.83%
P/E Excl Extra (TTM)16.50x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.22
P/TBV (Quarterly)4.60x
P/B Ratio (Annual)6.63x
Inventory Turnover (TTM)2.65x
Pretax Margin (TTM)15.10%
Book Value / Share (Annual)$0.96
Price vs S&P 500 (13W)-35.23%
Beta2.07x
P/FCF (Annual)23.27x
Revenue / Share (TTM)$1.54
ROE (TTM)25.38%
52-Week Low$3.57
vGradeC
gGradeB
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.07est. 0.07
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceutical Preparations(17)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NAGENiagen Bioscience, Inc. Common Stock | C | B | D | $3.61 |
| DFTXDefinium Therapeutics, Inc. Common Shares | — | — | A | $24.06 |
| CRONCronos Group Inc. Common Share | C | B | B | $2.82 |
| TLRYTilray Brands, Inc. Common Stock | B | B | D | $5.49 |
| CGCCanopy Growth Corporation Common Shares | B | D | D | $1.08 |
| USNAUSANA Health Sciences Inc | B | D | D | $18.33 |
| SNDLSundial Growers Inc. Common Shares | A | C | C | $1.46 |
| ACBAurora Cannabis Inc. Common Shares | B | D | D | $3.64 |
| MDWDMediWound Ltd. | D | F | D | $13.82 |
| FTLFFitLife Brands, Inc. Common Stock | B | C | D | $9.91 |
| BTMDBiote Corp. Class A Common Stock | A | D | D | $2.11 |
About
Niagen Bioscience Inc develops NAD+-boosting therapeutics focused on extending healthspan and addressing age-related decline. The company's clinically proven flagship ingredient effectively raises NAD+ levels and serves as the foundation for its product portfolio. Leveraging precision science approaches, Niagen targets the growing healthy-aging market with evidence-based solutions.